Bladder Cancer
PDO Screen
Off-the-shelf translational solutions for your preclinical drug development
Bladder cancer (BC) remains the most common malignancy of the urinary tract and its incidence is projected to grow in the next decade. Despite several improvements in the treatment of BC patients, the long-term survival rates of patients with BC have remained unchanged. This emphasizes the urgent need for clinically-relevant models that can be used at the preclinical stage for the development of novel therapies. Our patient-derived organoid (PDO) screen panel consists of bladder cancer organoid models selected for growth rate, pathology, and genetic profiles to represent the patient population. By enrolling in PDO Screen, you can either identify a lead agent from your library of compounds or evaluate the efficacy and potency of your agent across models predictive of patient response in the clinic.
Characterization of bladder cancer organoid panel
A) A representative brightfield image depicting bladder cancer organoid B) Histological analysis validates the bladder cancer origin of organoids derived from patient tumor tissue. In normal tissue., the urothelium exhibits organized and defined characteristics, while in tumor tissue, it displays a disorganized morphology C)Dose-response curves illustrating the response of sample PDOs to standard of care (SoC) treatments Erdafitinib and Gemcitabine
